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Abstract
Thousands of risk variants underlying complex phenotypes (quantitative traits and diseases)
have been identified in genome-wide association studies (GWAS). However, there are still two
major challenges towards deepening our understanding of the genetic architectures of complex
phenotypes. First, the majority of GWAS hits are in the non-coding region and their biological
interpretation is still unclear. Second, accumulating evidence from GWAS suggests the poly-
genicity of complex traits, i.e., a complex trait is often affected by many variants with small or
moderate effects, whereas a large proportion of risk variants with small effects remains unknown.
The availability of functional annotation data enables us to address the above challenges. In
this study, we propose a latent sparse mixed model (LSMM) to integrate functional annota-
tions with GWAS data. Not only does it increase statistical power of the identification of risk
variants, but also offers more biological insights by detecting relevant functional annotations.
To allow LSMM scalable to millions of variants and hundreds of functional annotations, we
developed an efficient variational expectation-maximization (EM) algorithm for model param-
eter estimation and statistical inference. We first conducted comprehensive simulation studies
to evaluate the performance of LSMM. Then we applied it to analyze 30 GWAS of complex
phenotypes integrated with 9 genic category annotations and 127 tissue-specific functional an-
notations from the Roadmap project. The results demonstrate that our method possesses more
statistical power over conventional methods, and can help researchers achieve deeper under-
standing of genetic architecture of these complex phenotypes. The LSMM software is available
at https://github.com/mingjingsi/LSMM.
∗Correspondence should be addressed to Can Yang (macyang@ust.hk) and Jin Liu (jin.liu@duke-nus.edu.sg)
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1 Introduction
Since the success of the first GWAS on age-related macular degeneration [Klein et al., 2005], more
than 40,000 single-nucleotide polymorphisms (SNPs) have been reported in about 3,100 GWAS at
the genome-wide significance level (see GWAS Catalog http://www.ebi.ac.uk/gwas/) [Welter et al.,
2014]. Despite these fruitful discoveries, the emerging evidence from GWAS presents great challenges
towards deeper understanding of the genetic architectures of complex phenotypes. First, more than
85% genome-wide significant hits are located in the non-coding region [Welter et al., 2014] and thus
their functional roles are still largely elusive. Second, complex phenotypes are often highly polygenic,
i.e., they are affected by a vast number of risk variants with individually small effects. For example,
70%-80% of the variation in human height can be attributed to genetics [Visscher et al., 2008].
However, Wood et al. [2014] collected more than 250,000 samples and identified 697 variants at
genome-wide significance level, and all these variants together can only explain 20% of heritability.
A recent estimate [Boyle et al., 2017] suggests that about 100,000 variants may be associated with
human height. Given current sample sizes, a large proportion of risk variants underlying complex
phenotypes remain unknown yet.
Fortunately, an increasing number of reports suggest that the functional importance of SNPs may
not be equal [Schork et al., 2013], which provides a direction to address the above challenges. On one
hand, SNPs in or near genic regions can explain more heritability of complex phenotypes [Yang et al.,
2011, Smith et al., 2011]. For example, the partition of genic category annotations for SNPs have
revealed that SNPs in 5’ UTR, exon and 3’ UTR are significantly enriched across diverse complex
traits [Schork et al., 2013]. On the other hand, tissue-specific functional annotations can provide
information that is complementary to genic category annotations, for dissecting genetic contribution
to complex diseases in a tissue-specific manner. To name a few, genetic variants related to functions
of immune cells are significantly enriched for immune diseases, such as rheumatoid arthritis, coeliac
disease and type 1 diabetes; variants with liver functions are enriched for metabolic traits, such as
LDL, HDL and total cholesterol; variants with pancreatic islet functions are enriched for fasting
glucose [Kundaje et al., 2015]. Additionally, SNPs in genes that are preferentially expressed in the
central nervous system are significantly enriched in psychiatric disorders (e.g., schizophrenia and
bipolar disorder) [Chung et al., 2014].
A large amount of functional annotation data has become publicly available and the volume is
still expanding. The Encyclopedia of DNA Elements (ENCODE) project [The ENCODE Project
Consortium, 2012] have conducted more than 1,650 experiments on 147 cell lines to access functional
elements across the human genome, such as DNase I hypersensitive sites and transcription factor
binding. The NIH Roadmap Epigenomics Mapping Consortium [Kundaje et al., 2015] is generating
high-quality genome-wide human epigenomic maps of histone modifications, chromatin accessibility,
DNA methylation and mRNA expression across more than one hundred of human cell types and
tissues.
With the availability of rich functional annotations, we aim to (1) integrate genic category an-
notations and tissue-specific functional annotations with GWAS to increase the statistical power of
the identification of risk SNPs, and (2) detect relevant tissue-specific functional annotations among
a large amount of available annotation data to have a more biologically insightful interpretation of
GWAS results. Statistical methods to incorporate genic category annotations have been proposed,
e.g., stratified FDR methods [Schork et al., 2013], cmfdr [Zablocki et al., 2014], GPA [Chung et al.,
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2014] and EPS [Liu et al., 2016]. However, these methods were designed to handle a few number of
functional annotations and can not be scalable to a large-scale integrative analysis.
In this study, we propose a Latent Sparse Mixed Model (LSMM) to integrate genic category
annotations and tissue-specific functional annotations with GWAS data. The “latent" statuses are
used to connect the observed summary statistics from GWAS with functional annotations. “Mixed"
models are designed to simultaneously consider both genic category and tissue-specific annotations,
where genic category annotations are put into the design matrix of fixed effects, and tissue-specific
annotations are encoded in the design matrix of random effects. We further impose a “sparse" struc-
ture on the random effects to adaptively select relevant tissue-specific annotations. We conducted
comprehensive simulations to investigate the properties of LSMM and then applied LSMM to real
data. We integrated summary statistics from 30 GWAS with 9 genic category annotations and
127 tissue-specific functional annotations from the Roadmap project. Compared with conventional
methods, our method is able to increase the statistical power in the identification of risk variants and
detection of tissue-specific functional annotations and providing a deeper understanding of genetic
architecture of complex phenotypes.
2 Latent Sparse Mixed Model (LSMM)
2.1 Model
Suppose we have the summary statistics (p-values) ofM SNPs from GWAS. Consider the two-groups
model [Efron, 2008], i.e., SNPs either belong to null or non-null group. Let γj be the latent variable
indicating the membership of the j-th SNP, i.e., γj = 0 or γj = 1 indicates the j-th SNP from null
or non-null group, respectively. We further denote the proportion of null and non-null group as pi0
and pi1, respectively. Then we model the observed p-values as [Chung et al., 2014],
pj ∼
U [0, 1] , γj = 0,Beta (α, 1) , γj = 1, (1)
where U [0, 1] denotes the uniform distribution on [0,1] and Beta(α, 1) is the beta distribution with
parameter (α, 1). We constrain 0 < α < 1 to model the fact that p-values from the non-null group
tend to be closer to 0 rather than 1.
Suppose that we have collected not only the p-values ofM SNPs from GWAS, but also functional
annotations of these SNPs. To incorporate information from functional annotations for prioritization
of risk variants and detection of tissue-specific functions for a complex phenotype, we consider the
following latent sparse mixed model:
log
Pr (γj = 1|Zj ,Aj)
Pr (γj = 0|Zj ,Aj) = Zjb + Ajβ, (2)
where Z ∈ RM×(L+1) is the design matrix for fixed effects, comprised of an intercept and L covariates,
b ∈ RL+1 is the vector of fixed effects, A ∈ RM×K is the design matrix for random effects, β ∈ RK
is the vector of random effects, and K is the number of random effects. Both the j-th row of Z (i.e.,
Zj) and A (i.e., Aj) corresponds to the j-th SNP. Note that γj is a latent variable in model (2)
3
but its corresponding pj is observed. This makes our model different from the standard generalized
linear mixed model.
Now we partition functional annotations into two categories: genic category annotations and
tissue-specific annotations. According to [Schork et al., 2013], genomic regions, such as exon, intron,
5’UTR and 3’UTR, are considered as genic category annotations. For tissue-specific annotations, we
used epigenetic markers (H3k4me1, H3k4me3, H3k36me3, H3k27me3, H3k9me3, H3k27ac, H3k9ac,
and DNase I Hypersensitivity) of multiple tissues from the Roadmap project. As we are more
interested in the detection of tissue-specific results, we put genic category annotation data into Z
and tissue-specific annotation data into A, where each column of Z corresponds to a genic functional
category and each column of A corresponds to a tissue-specific functional category. In the simplest
case, the entries in Z and A are binary. For example, Zjl = 1 means that the j-th SNP has a
function in the l-th genic category and Zjl = 0 otherwise. Our model also allows the entries in Z
and A to be continuous variables, e.g., a score Zjl between 0 and 1 can be used to indicate the
degree that the j-the SNP has a function in the l-th category. The closer to 1, the more likely it has
a functional role. The entries in A are defined in the same way as those of Z.
To adaptively select tissue-specific annotations, we assign a spike-slab prior on βk:
βk ∼
N
(
βk|0, σ2
)
, ηk = 1,
δ0 (βk) , ηk = 0,
(3)
where N
(
βk|0, σ2
)
denotes the Gaussian distribution with mean 0 and variance σ2, δ0 denotes the
Dirac delta function at zero, ηk = 1 or ηk = 0 means the k-th annotation is relevant or irrelevant to
the given phenotype, respectively. Here ηk is a Bernoulli variable with probability ω being 1:
ηk ∼ ωηk(1− ω)1−ηk , (4)
where ω can be interpreted as the proportion of relevant annotations corresponding to this phenotype.
Let θ =
{
α,b, σ2, ω
}
be the collection of model parameters. The logarithm of the marginal
likelihood can be written as
log Pr (p|Z,A;θ) = log
∑
γ
∑
η
ˆ
Pr (p,γ,β,η|Z,A;θ) dβ, (5)
where
Pr (p,γ,β,η|Z,A;θ) = Pr (p|γ;α) Pr (γ|Z,A,β;b) Pr (β|η;σ2)Pr (η|ω) . (6)
Our goal is to maximize the marginal likelihood to obtain the estimation θˆ of θ and compute the
posterior
Pr
(
γ,β,η|p,Z,A; θˆ
)
=
Pr
(
p,γ,β,η|Z,A; θˆ
)
Pr
(
p|Z,A; θˆ
) . (7)
Then we can infer the risk SNPs and relevant tissue-specific functional annotations for this phenotype
and calculate the false discovery rate.
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2.2 Algorithm
Exact evaluation of posterior (7) is intractable. One difficulty is due to the sigmoid function resulting
from the logistic model. The other comes from the spike-slab prior. To address this issue, we propose
a variational EM algorithm for parameter estimation and posterior approximation.
Before starting the derivation of our algorithm, we first re-parametrize the spike-slab prior (3) by
introducing a new Gaussian variable β˜k ∼ N
(
0, σ2
)
, then the product ηkβ˜k has the same distribution
with βk in model (3). So model (2) can be written as
log
Pr (γj = 1|Zj ,Aj)
Pr (γj = 0|Zj ,Aj) = Zjb +
K∑
k=1
Ajkβk = Zjb +
K∑
k=1
Ajkηkβ˜k. (8)
Hence the complete-data likelihood Pr (p,γ,β,η|Z,A;θ) can be re-written as
Pr
(
p,γ, β˜,η|Z,A;θ
)
= Pr (p|γ;α) Pr
(
γ|Z,A, β˜,η;b
)
Pr
(
β˜,η|σ2, ω
)
, (9)
where
Pr (p|γ;α) =
M∏
j=1
Pr (pj |γj ;α) =
M∏
j=1
(
αpα−1j
)γj
, (10)
Pr
(
γ|Z,A, β˜,η;b
)
=
M∏
j=1
Pr
(
γj |Zj ,Aj , β˜,η;b
)
=
M∏
j=1
eγj(Zjb+
∑
k Ajkηkβ˜k)S
(
−Zjb−
K∑
k=1
Ajkηkβ˜k
)
, (11)
Pr
(
β˜,η|σ2, ω
)
= Pr
(
β˜|σ2
)
Pr (η|ω) =
K∏
k=1
N
(
β˜k|0, σ2
)
ωηk (1− ω)1−ηk , (12)
where S (·) is the sigmoid function and S (x) = (1 + e−x)−1. With this reparameterization, we get
rid of the Dirac delta function.
Due to the intractability caused by the sigmoid function inside integration (5), we consider the
JJ bound [Jaakkola and Jordan, 2000]:
S (x) ≥ S (ξ) exp{(x− ξ) /2− λ (ξ) (x2 − ξ2)} , (13)
where λ (ξ) = 12ξ
[
S (ξ)− 12
]
and the right-hand-side of the inequality (13) is the JJ bound. Clearly,
the JJ bound is in the exponential of a quadratic form. Applying this bound to (11), we can get a
tractable lower bound of Pr
(
γ|Z,A, β˜,η;b
)
, denoted as h
(
γ|Z,A, β˜,η;b, ξ
)
, where ξ ∈ RM is
variational parameter. Let Θ =
{
α,b, ξ, σ2, ω
}
. The lower bound of the complete-data likelihood
is defined as
f
(
p,γ, β˜,η|Z,A;Θ
)
= Pr (p|γ;α)h
(
γ|Z,A, β˜,η;b, ξ
)
Pr
(
β˜,η|σ2, ω
)
. (14)
Next we derive the variational EM algorithm. Let q
(
γ, β˜,η
)
be an approximation of the poste-
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rior Pr
(
γ, β˜,η|p,Z,A;θ
)
. We can obtain a lower bound of the logarithm of the marginal likelihood
log Pr (p|Z,A;θ)
= log
∑
γ
∑
η
ˆ
Pr
(
p,γ, β˜,η|Z,A;θ
)
dβ˜
≥ log
∑
γ
∑
η
ˆ
f
(
p,γ, β˜,η|Z,A;Θ
)
dβ˜
≥
∑
γ
∑
η
q
(
γ, β˜,η
)
log
f
(
p,γ, β˜,η|Z,A;Θ
)
q
(
γ, β˜,η
) dβ˜
=Eq
[
log f
(
p,γ, β˜,η|Z,A;Θ
)
− log q
(
γ, β˜,η
)]
,L (q) , (15)
where L(q) is the lower bound. The first inequality is based on the JJ bound. The second inequality
follows Jensen’s inequality. To make it feasible to evaluate the lower bound, we use the mean-field
theory and assume that q
(
γ, β˜,η
)
can be factorized as
q
(
γ, β˜,η
)
=
(
K∏
k=1
q
(
β˜k, ηk
)) M∏
j=1
q (γj)
 , (16)
where q
(
β˜k, ηk
)
= q
(
β˜k|ηk
)
q (ηk). It turns out that q
(
γ, β˜,η
)
can be obtained analytically and
thus the lower bound L(q) can be exactly evaluated. By setting the derivative of L(q) with respect
to the parameters in Θ be zero, we can obtain the updating equations for parameter estimation.
The detailed derivation of the algorithm can be found in Section 1 of Supplementary Document.
We note that LSMM covers two special cases: (1) Two-groups model only (denoted as TGM),
when all the coefficients in b (except the intercept term) and β are zero; (2) Two-groups model plus
fixed effects model only (denoted as LFM for the abbreviation of latent fixed effect model), when all
coefficients in β are zero. This motivates us developing a four-stage algorithm based on warm starts.
More specifically, in the first stage, we run an EM algorithm to obtain the two parameters (α and the
proportion of non-null group pi1) in the TGM. Then we use the estimated parameters as the starting
point to run the second stage variational EM algorithm to fit the LFM and obtain the parameter α,
b and the posterior probability of γ. In the third stage, we treat the obtained posterior as the value
of γ and fit the logistic sparse mixed model to obtain the required initial value for the parameters
in the next stage. Finally, in the fourth stage we run the above variational EM algorithm with
the obtained parameters at the second and third stage until convergence. Since all the iterations
are built upon the framework of EM algorithm, the lower bound is guaranteed to increase at each
iteration. The details of the algorithm design are provided in Section 2 of Supplementary Document.
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2.3 Identification of risk SNPs and Detection of relevant tissue-specific
functional annotations
After the convergence of the variational EM algorithm, the approximated posterior of latent variables
γ and η can be obtained. Using this information, we are able to prioritize risk SNPs and relevant
tissue-specific functional annotations.
Risk SNPs are identified based on q (γj = 1), an approximation of the posterior probability that
the j-th SNP is associated with this phenotype. Accordingly, we can calculate the approximated
local false discovery rate fdrj = 1 − q (γj = 1). To control the global false discovery rate (FDR),
we sort SNPs by fdr from the smallest to the largest and regard the j-th re-ordered SNP as a risk
SNP if
FDR(j) =
∑j
i=1 fdr(j)
j
≤ τ, (17)
where fdr(j) is the j-th ordered fdr, FDR(j) is the corresponding global FDR, and τ is the threshold
of global FDR. In simulations, we chose τ = 0.1.
Relevant tissue-specific functional annotations are inferred from q (ηk = 1), an approximation of
the posterior probability that annotation k is relevant to this phenotype. Similarly, we can calculate
the approximated local false discovery rate fdrk = 1− q (ηk = 1) and convert it into the global false
discovery rate. We can either control the local false discovery rate (e.g., fdrk ≤ 0.1) or global false
discovery rate with τ = 0.1.
3 Results
3.1 Simulation
We conducted simulations to evaluate the performance of the proposed LSMM. The simulation
data was generated as follows. The numbers of SNPs, fixed effects (genic category annotations) and
random effects (tissue-specific functional annotations) were set to beM = 100, 000, L = 10 and K =
500 respectively. The entries in design matrices Zjl and Ajk were generated from Bernoulli (0.1),
j = 1, ...,M , l = 1, ..., L and k = 1, ...,K. Given the proportion of relevant tissue-specific functional
annotations ω, ηk was drawn from Bernoulli (ω) and the corresponding nonzero entries of random
effects β were simulated from N (0, 1). The first entry of the coefficients of fixed effects b, i.e., the
intercept in the logistic model, was fixed at −2 and other entries were generated from N (0, 1) and
then kept fixed in multiple replications. After that, we simulated γj from Bernoulli distribution with
probability S (Zjb + Ajβ), and then generated pj from U [0, 1] if γj = 0 and Beta (α, 1) otherwise.
We first evaluated the performance of LSMM in the identification of risk SNPs. We compared
LSMM with two special cases, LFM (with fixed effects only) and TGM (without fixed effects and
random effects). After prioritizing the risk SNPs using these methods, we made a comparison upon
their empirical FDR, power, area under the receiver operating characteristic curve (AUC) and partial
AUC. We varied the proportion of relevant random effects ω at {0, 0.01, 0.05, 0.1, 0.2}. Figure 1 shows
the performance of these three models with α = 0.2 and K = 500 (results for other scenarios are
shown in Figures S2-S9 in Supplementary Document). As shown in Figure 1, the empirical FDRs are
indeed controlled at the nominal level (τ = 0.1) for all these models. For TGM and LFM, the powers
increase as the proportion of relevant functional annotations ω increases. This is because a larger ω
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could result in an increasing proportion of non-null group for SNPs. However, the AUC and partial
AUC of LFM slightly decrease because the estimates of fixed effects using LFM would become less
accurate when the impact of functional annotations becomes larger. LSMM can adaptively select
relevant functional annotations to improve its performance. As expected, it outperforms both TGM
and LFM in terms of the power, AUC and partial AUC. One may wonder what if we do not do
variable selection and simply treat the effects of all covariates as fixed effects. We evaluated this
approach and found that, without variable selection, the FDR would be inflated when the GWAS
signal is relatively weak (See Figure S10 in Supplementary Document). In addition, LSMM assumed
independence among SNPs, which greatly facilitates the computation and inference of LSMM. We
evaluated the impact of this assumption on LSMM. The details of the simulations are given in Section
3 of Supplementary Document. Because GWAS only aim to identify the local genomic region in LD
with true risk genetic variants, it is reasonable to consider the identified SNPs not as false positives
if they are in the flanking region of the true risk SNPs. In this sense, the results (Figure S1 in
Supplementary Document) suggest that LSMM can provide a satisfactory FDR control.
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Figure 1: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.2 and K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
Next we evaluated the performance of LSMM in the detection of relevant tissue-specific functional
annotations in terms of the FDR, power, AUC and partial AUC. We varied the proportion of
relevant tissue-specific functional annotations ω at {0.01, 0.05, 0.1, 0.2}. The results with α = 0.2
and K = 500 are given in Figure 2 (results for other scenarios are shown in Figures S11-S18 in
Supplementary Document). The empirical FDR is controlled at 0.1 with conservativeness. This
is because the variational approach is adopted to approximate the posterior, e.g., the JJ bound
and mean-field approximation. The performance of LSMM in the detection of relevant functional
annotations depends on the signal strength of the GWAS data. When the signal of the GWAS
data is relatively strong, i.e., α is relatively small, LSMM has a very good performance of detecting
relevant functional annotations, as indicated by power, AUC and partial AUC. We also conducted the
following simulations to examine the role of adjusting covariates (i.e., genic category annotations)
using fixed effects for detecting relevant tissue-specific annotations. We consider the case that
genic category annotations and some tissue-specific annotations are correlated and b, the vector
of coefficients corresponding to genic category annotations, is nonzero. Without adjusting genic
category annotations, some irrelevant tissue-specific annotations will be falsely included in the model
due to their correlation with genic category annotations. To verify this, we simulated a case that
10 genic category annotations and first 50 tissue-specific annotations are correlated with correlation
coefficient varied at {0, 0.2, 0.4, 0.6, 0.8} and the remaining annotations are generated independently.
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To simulate the design matrices for genic category and tissue-specific annotations, we first simulated
M samples from a multivariate normal distribution with the correlation matrix among annotations
and then made a cutoff so that 10% of the entries would be 1 and the others be 0. The results
are shown in Figure S19 in Supplementary Document. In the presence of correlation, as expected,
a larger FDR of detecting relevant tissue-specific annotations is observed without adjusting genic
category annotations.
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Figure 2: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations with
α = 0.2 and K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and power. The
results are summarized from 50 replications.
Regarding parameter estimation, LSMM provides a satisfactory estimate of α, the parameter in
Beta distribution (See Figures S31-S33 in Supplementary Document). When the signal strength of
GWAS data is not very weak, the estimated fixed effects b (Figures S34-S44 in Supplementary Doc-
ument) and the proportion of non-zero random effects ω (Figure S45 in Supplementary Document)
are relatively accurate.
The computational time of LSMM depends on the strength of GWAS signal, the number of SNPs
and the number of random effects. The left panel of Figure 3 shows that the computational time
is nearly linear with respect to M and K with α = 0.2. In the right panel, we fixed M = 100, 000
and varied K and α. When the GWAS signal is relatively weak, e.g., α = 0.6, the timings of LSMM
remain the same for different scales of random effects. This is because LSMM adopts a warm-start
strategy and its last two stages start from the estimates at the second stage (i.e., fixed effects only)
and converge in a few iterations because the GWAS signal is too weak to provide information for
updating the random effects.
To test the robustness of LSMM, instead of using generative model (2), we conducted simulations
based on probit model:
yj = Zjb + Ajβ + ej , (18)
where ej ∼ N
(
0, σ2e
)
. And we set γj = 1 if yj > 0, γj = 0 if yj ≤ 0. The first entry of the
coefficients of fixed effects b, i.e. the intercept term, was fixed at −1 and other entries were generated
from N (0, 1) and fixed during multiple replications. We set α = 0.2 and varied the signal-noise
ratio r = {4 : 1, 1 : 1, 1 : 4}. Figure 4 shows the performance in identification of risk SNPs when
K = 500. We note that FDRs are all well-controlled at the nominal level and LSMM shows the best
performance in power, AUC and partial AUC. The advantages of LSMM over LFM and TGM is more
apparent as the signal-noise ratio increases. The performance of LSMM in the detection of relevant
functional annotations is provided in Figure 5. Results for other scenarios are shown in Figures S20-
S23 in Supplementary Document. Furthermore, we simulated the underlying distribution of p-values
in non-null group from other distributions rather than the Beta distribution. The experimental
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Figure 3: Computational time of LSMM. Left panel: We varied the number of SNPs M and the
number of random effects K, with α = 0.2. Right panel: We varied the number of random effects
K and the strength of GWAS signal α with M = 100, 000. The results are summarized from 10
replications.
results indicate that the FDR of LSMM is still well controlled at the nominal level, suggesting
the robustness of LSMM and its potentially wide usage (results are shown in Figures S24-S26 in
Supplementary Document).
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Figure 4: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs based on probit model (18) with K = 500. We controlled global FDR at 0.1 to evaluate
empirical FDR and power. The results are summarized from 50 replications.
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Figure 5: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for detection of relevant
annotations based on probit model with K = 500. We controlled global FDR at 0.1 to evaluate
empirical FDR and power. The results are summarized from 50 replications.
We compared LSMM with GPA in the identification of risk variants and detection of tissue-
specific annotations. As LSMM can integrate both genic category and functional annotations, we
compared GPA with LSMM without fixed effects (integrate functional annotations only) for a fair
comparison. From the model setup, one main difference between GPA and LSMM is that GPA
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assumes conditional independence among annotations, whereas in LSMM we do not make this
assumption. To check the influence of correlated functional annotations, we simulated a case that the
first 10 functional annotations were correlated and all the others were independent. We set α = 0.2
and varied the correlation among annotations corr at {0, 0.2, 0.4, 0.6, 0.8}. To simulate the design
matrices for correlated functional annotations, we first simulated M samples from a multivariate
normal distribution with the correlation matrix among annotations and then made a cutoff so that
10% of the entries would be 1 and the others be 0. Figure 6 shows the results with K = 500 (results
for other scenarios are shown in Figures S27-S29 in Supplementary Document). We observe that
the empirical FDRs of LSMM and LSMM without fixed effects are indeed controlled at 0.1, but
the FDR of GPA inflates very much when annotations are correlated. As the FDR of GPA is not
controlled, the power of GPA is not comparable to the other two models. According to the AUC
and partial AUC, the performance of GPA becomes worse as the correlation among annotations
increase, while the performance of LSMM is still stable and outstanding. It implies that LSMM
is able to identify true relevant annotations among correlated misleading ones. We also conducted
simulations to compare LSMM with cmfdr, a fully Bayesian approach to incorporate genic category
annotations in GWAS using MCMC sampling algorithm. We find that cmfdr is not able to handle a
large number of annotations and the MCMC sampling algorithm is very time-consuming. The result
is shown in Figure S30 in Supplementary Document. Besides the computational time, we observe
the empirical FDR of cmfdr is slightly inflated and its performance for prioritization of risk variants
is inferior to LSMM in terms of AUC and partial AUC.
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Figure 6: FDR, power, AUC and partial AUC of LSMM, LSMM without fixed effects and GPA for
identification of risk SNPs with K = 500. We controlled global FDR at 0.1 to evaluate empirical
FDR and power. The results are summarized from 50 replications.
3.2 Real Data Analysis
We applied LSMM to analyze 30 GWAS of complex phenotypes. The source of the 30 GWAS is given
in Table S2 in Supplementary Document. We used ANNOVAR [Wang et al., 2010] to provide the
genic category annotations: upstream, downstream, exonic, intergenic, intronic, ncRNA_exonic,
ncRNA_intronic, UTR3 and UTR5, where ncRNA means variant overlaps a transcript without
coding annotation in the gene definition. We obtained 127 tissue-specific functional annotations
from GenoSkylinePlus [Lu et al., 2017] (http://genocanyon.med.yale.edu/GenoSkyline). To avoid
unusually large GWAS signals in the MHC region (Chromosome 6, 25Mb - 35Mb), we excluded the
SNPs in this region.
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We compared the number of identified risk SNPs using TGM, LFM and LSMM for 30 GWAS.
Using LSMM as a reference, we calculated the ratio of the number of risk SNPs each method identified
to that from LSMM under FDR thresholds τ = 0.05 and τ = 0.1. The results are shown in Figure
7. For detecting the relevant tissue-specific functional annotations, we controlled the local fdr at
0.1. Figure 8 shows the approximated posterior probability for annotations and phenotypes, where
the darkness of the red entry implies the level of relevance between the corresponding tissue-specific
functional annotation and the phenotype, the darker the more relevant.
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Figure 7: The number of risk variants identified by TGM, LFM and LSMM for 30 GWAS, under
the same level of global FDR control (0.05 and 0.1). For visualization purpose, these numbers are
normalized by dividing the corresponding number of variants identified by LSMM.
Figure 7 shows that LSMM can identify more risk variants than TGM and LFM, under the same
level of FDR control. The differences between TGM and LFM is due to the impact of genic cate-
gory annotations and the differences between LFM and LSMM can be attributed to tissue-specific
functional annotations. For HIV and bipolar disorder, a clear improvement in the identification of
risk SNPs can be found from TGM to LFM, reflecting a large enrichment of genic category annota-
tions. The contribution of tissue specific annotations can be clearly seen with the improvement from
LFM to LSMM in several GWAS analyses, such as multiple sclerosis and coronary artery disease
(CAD). For multiple sclerosis, genic category annotations do not show huge contributions, however,
the contributions of tissue-specific annotations are substantial. As shown in Figure 8, its relevant
tissue-specific annotations are related with immune system, GM12878 lymphoblastoid cells and pri-
mary B cells from peripheral blood. For CAD, both enrichment of genic category and tissue-specific
annotations are estimated and its relevant cells are from a few different tissues, including blood,
heart, lung and skin (See Figure 8). As a cardiovascular disease, it is reasonable to discover the
relevance of these cells to CAD, and Fernández-Ruiz [2016] has shown its relationship with immune
system. The annotations in lung and skin we detected may provide some new insights about the
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Figure 8: Relevant tissue-specific functional annotations for 30 GWAS.
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disease.
Among the 30 GWAS, we analyzed four GWAS of schizophrenia with different sample sizes,
Schizophrenia1 (9,379 cases and 7,736 controls), Schizophrenia2 (9,394 cases and 12,462 controls),
Schizophrenia3 (13,833 cases and 18,310 controls ) and Schizophrenia4 (36,989 cases and 113,075
controls). The detailed results are summarized in Table S3 in Supplementary Document. The
Manhattan plots using TGM and LSMM are provided in Figure S46 in Supplementary Document.
Clearly, LSMM steadily improves over TGM and LFM in the analysis of schizophrenia, a highly
polygenic trait, with different sample sizes. In particular, for Schizophrenia3, LSMM identified 1,492
risk variants which could not be identified by TGM. Interestingly, the majority of them (872 variants)
can be re-identified in Schizophrenia4 using TGM. This indicates that LSMM has a better power in
prioritizing risk variants than TGM. For Schizophrenia4, four tissue-specific functional annotations
are detected. In our analysis, both genetic variants related to functions of brain cells (brain angular
gyrus) and blood cells (K562 leukemia cells) are detected to be relevant. This evidence not only
connects Schizophrenia with brain, but also suggests the biological link between Schizophrenia and
immune system [Ripke et al., 2014]. We also analyzed two GWAS of years of education (Years of
Education 1 and 2). Compared with Years of Eduction 1, the GWAS data set for Years of Education
2 is based on a larger sample size, and thus it enables LSMM to detect relevant functional annotations
in brain and immune system. Our results are consistent with Finucane et al. [2015].
More findings about the relevance between tissue-specific annotations and GWAS are shown in
Figure 8. Some are concordant with previous GWAS analyses. For example, we detect the functional
annotation in liver to be relevant to the lipid-related phenotypes, including low-density lipoprotein,
high-density lipoprotein, triglycerides and total cholesterol. Similar functional enrichment has been
found by Kundaje et al. [2015], Finucane et al. [2015] and Lu et al. [2017]. For height, more than
40 tissue-specific functional annotations are detected to be relevant using LSMM, which reflects its
highly polygenic genetic architecture. These relevant annotations include cells in bone, vascular and
skeletal muscle which were also shown significant enrichments for height by Finucane et al. [2015].
Recent research has linked some neurodegenerative diseases, which were believed to be more related
to brain and neural system, to the immune system, such as Alzheimer’s disease [Sims et al., 2017]
and Parkinson’s disease [Sulzer et al., 2017]. For Alzheimer’s disease, similar results have been
found using LSMM. The relevant functional annotations are from blood cells, including monocytes-
CD14+ and K562 leukemia cells. For autoimmune diseases including Crohn’s disease, ulcerative
colitis, inflammatory bowel disease, rheumatoid arthritis, lupus, menopause, multiple sclerosis and
primary biliary cirrhosis, the detected relevant functional annotations are mainly from the immune
system and have many overlaps. Our results also provide the genomic level supports to previous
medical literature, such as the relevance between spleen and inflammatory bowel disease [Muller
et al., 1993], between liver and menopause [Mucci et al., 2001]. The result also provides several
new insights. Lipid-related phenotypes including high-density lipoprotein and total cholesterol are
also relevant to functional annotations in immune system and brain. Additionally, annotations in
immune system are considered relevant to blood-related phenotypes including red cell count, mean
cell haemoglobin and mean cell volume. The foreskin fibroblast primary cells in skin are relevant to
ulcerative colitis, four lipid-related phenotypes and red cell count.
Regarding the computational time, LSMM takes less than six minutes to handle each of the 30
GWAS datasets. We also recorded timings of cmfdr as a comparison. As cmfdr is not scalable to
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a large number of covariates, we only integrated the 9 genic category annotations in cmfdr. The
MCMC algorithm was suggested [Zablocki et al., 2014] to run with 5,000 burn-in and 20,000 main
iterations. According to our estimates, cmfdr takes more than ten days for most phenotypes. The
detailed timing results are shown in Figure S47 of Supplementary Document.
If we did not adjust the genic category annotation, more relevant tissue-specific functional an-
notations would be detected (results are shown in Figure S48 in Supplementary Document). It
indicates that LSMM could adjust covariates’ effects and provide a more reliable identification of
relevant functional annotations.
4 Conclusion
We have presented a statistical approach, LSMM, to integrate genic category annotations and a large
amount of tissue-specific functional annotations with GWAS data. LSMM can not only improve the
statistical power in the identification of risk SNPs, but also infer relevant tissue-specific functional
annotations to the phenotype, offering new insights to explore the genetic architecture of complex
traits or diseases. Through comprehensive simulations and real data analysis of 30 GWAS, LSMM
is shown to be statistically efficient and computationally scalable. As more annotation data will
become publicly available in the future, we believe LSMM is widely useful for integrative analysis of
genomic data.
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E-step
Let θ =
{
α,b, σ2, ω
}
be the collection of model parameters. The logarithm of the marginal likelihood
is
log Pr (p|Z,A;θ) = log
∑
γ
∑
η
ˆ
Pr
(
p,γ, β˜,η|Z,A;θ
)
dβ˜.
Using the signoid function denoted as S (x) = 11+e−x , the complete-data likelihood can be written
as
Pr
(
p,γ, β˜,η|Z,A;θ
)
= Pr (p|γ;α) Pr
(
γ|Z,A, β˜,η;b
)
Pr
(
β˜,η|σ2, ω
)
,
.where
Pr (p|γ;α) =
M∏
j=1
Pr (pj |γj ;α) =
M∏
j=1
(
αpα−1j
)γj
,
Pr
(
γ|Z,A, β˜,η;b
)
=
M∏
j=1
Pr
(
γj |Zj ,Aj , β˜,η;b
)
=
M∏
j=1
eγj(Zjb+
∑
k Ajkηkβ˜k)S
(
−Zjb−
∑
k
Ajkηkβ˜k
)
,
Pr
(
β˜,η|σ2, ω
)
=
K∏
k=1
Pr
(
β˜k, ηk|σ2, ω
)
=
K∏
k=1
N
(
β˜k|0, σ2
)
ωηk (1− ω)1−ηk .
We can use JJ bound [Jaakkola and Jordan, 2000] to get the tractable lower bound of Pr
(
γ|Z,A, β˜,η;b
)
which is denoted by h
(
γ|Z,A, β˜,η;b, ξ
)
:
Pr
(
γj |Zj ,Aj , β˜,η;b
)
= eγj(Zjb+
∑
k Ajkηkβ˜k)S
(
−Zjb−
∑
k
Ajkηkβ˜k
)
≥ eγj(Zjb+
∑
k Ajkηkβ˜k)S (ξj) exp
−λ (ξj)
(Zjb +∑
k
Ajkηkβ˜k
)2
− ξ2j
− Zjb +∑k Ajkηkβ˜k + ξj
2

= h
(
γj |Zj ,Aj , β˜,η;b, ξj
)
,
where
λ (ξj) =
1
2ξj
(
S (ξj)− 1
2
)
.
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Let Θ =
{
α,b, ξ, σ2, ω
}
. Then
f
(
p,γ, β˜,η|Z,A;Θ
)
= Pr (p|γ;α)h
(
γ|Z,A, β˜,η;b, ξ
)
Pr
(
β˜,η|σ2, ω
)
is a lower bound of complete-data likelihood.
Next, let q
(
γ, β˜,η
)
be an approximation of the posterior Pr
(
γ, β˜,η|p,Z,A;θ
)
. Then we can
obtain a lower bound of the logarithm of the marginal likelihood:
log Pr (p|Z,A;θ)
= log
∑
γ
∑
η
ˆ
Pr
(
p,γ, β˜,η|Z,A;θ
)
dβ˜
≥ log
∑
γ
∑
η
ˆ
f
(
p,γ, β˜,η|Z,A;Θ
)
dβ˜
≥
∑
γ
∑
η
ˆ
q
(
γ, β˜,η
)
log
f
(
p,γ, β˜,η|Z,A;Θ
)
q
(
γ, β˜,η
) dβ˜
= Eq
[
log f
(
p,γ, β˜,η|Z,A;Θ
)
− log q
(
γ, β˜,η
)]
, L (q) ,
where L(q) is the lower bound. The second inequality follows Jensen’s inequality. And
log Pr (p|γ, α)
=
M∑
j=1
(γj (logα+ (α− 1) log pj)) ,
log h
(
γ|Z,A, β˜,η,b, ξ
)
=
M∑
j=1
(
γj
(
Zjb +
∑
k
Ajkηkβ˜k
)
+ logS (ξj)
)
+
M∑
j=1
−λ (ξj)
(Zjb +∑
k
Ajkηkβ˜k
)2
− ξ2j
−(Zjb +∑
k
Ajkηkβ˜k + ξj
)
/2
 ,
log Pr
(
β˜,η|σ2, ω
)
= − 1
2σ2
K∑
k=1
β˜2k −
K
2
log
(
2piσ2
)
+
K∑
k=1
ηk logω +
K∑
k=1
(1− ηk) log (1− ω) .
To make it feasible to evaluate the lower bound, we assume that q
(
γ, β˜,η
)
can be factorized as
q
(
γ, β˜,η
)
=
(
K∏
k=1
q
(
β˜k, ηk
)) M∏
j=1
q (γj)
 ,
17
where q
(
β˜k, ηk
)
= q
(
β˜k|ηk
)
q (ηk),q (γj = 1) = pij , q (ηk = 1) = ωk.
We can obtain an approximation according to the mean-field method:
log q
(
β˜i, ηi
)
= Ek 6=iEγ
[
log f
(
p,γ, β˜,η|Z,A;Θ
)]
=
− 1
2σ2
−
M∑
j=1
λ (ξj)A
2
jiη
2
i
 β˜2i
+
M∑
j=1
(pij − 1
2
− 2λ (ξj)Zjb
)
Aji − 2λ (ξj)Aji
∑
k 6=i
AjkEk
[
ηkβ˜k
] ηiβ˜i
+ηi logω + (1− ηi) log (1− ω) + const,
where the expectation is taken under the distribtion q (γ) and q
(
β˜−i, η−i
)
=
∏
k 6=i q
(
β˜k, ηk
)
.
When ηi = 1, we have
log q
(
β˜i|ηi = 1
)
=
− 1
2σ2
−
M∑
j=1
λ (ξj)A
2
ji
 β˜2i
+
M∑
j=1
(pij − 1
2
− 2λ (ξj)Zjb
)
Aji − 2λ (ξj)Aji
∑
k 6=i
AjkEk
[
ηkβ˜k
] β˜i + const,
where Ek denotes the expectation under q
(
β˜k, ηk
)
, and the constant doesn’t depend on β˜i. Because
log q
(
β˜i|ηi = 1
)
is a quadratic form,
q
(
β˜i|ηi = 1
)
= N
(
µi, s
2
i
)
,
where
µi = s
2
i
M∑
j=1
pij − 1
2
− 2λ (ξj)
Zjb +∑
k 6=i
AjkEk
[
ηkβ˜k
]Aji
 ,
s2i =
σ2
1 + 2σ2
∑M
j=1 λ (ξj)A
2
ji
.
When ηi = 0, we have
log q
(
β˜i|ηi = 0
)
= − 1
2σ2
β˜2i + const.
So
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q
(
β˜i|ηi = 0
)
= N
(
0, σ2
)
.
Therefore we have
q
(
β˜i, ηi
)
=
[
ωiN
(
µi, s
2
i
)]ηi [
(1− ωi)N
(
0, σ2
)]1−ηi
.
Now we evaluate the variational lower bound L (q).
Eq [log Pr (p|γ, α)]
=
M∑
j=1
(pij (logα+ (α− 1) log pj)) ,
Eq
[
log h
(
γ|Z,A, β˜,η,b, ξ
)]
=
M∑
j=1
pij (Zjb +∑
k
Ajkωkµk
)
+ logS (ξj)− λ (ξj)
(Zjb +∑
k
Ajkωkµk
)2
− ξ2j

+
M∑
j=1
(
−
(
Zjb +
∑
k
Ajkωkµk + ξj
)
/2 + λ (ξj)
∑
k
A2jkω
2
kµ
2
k − λ (ξj)
∑
k
A2jkωk
(
s2k + µ
2
k
))
,
Eq
[
log Pr
(
β˜,η|σ2, ω
)]
= − 1
2σ2
K∑
k=1
(
ωk
(
s2k + µ
2
k
)
+ (1− ωk)σ2
)− K
2
log
(
2piσ2
)
+
K∑
k=1
ωk logω +
K∑
k=1
(1− ωk) log (1− ω) ,
−Eq
[
log q
(
γ, β˜,η
)]
=
K∑
k=1
(
1
2
ωk
(
log s2k − log σ2
)− ωk logωk − (1− ωk) log (1− ωk))+ K
2
log σ2 +
K
2
+
K
2
log (2pi)
−
M∑
j=1
(pij log pij + (1− pij) log (1− pij)) .
We set the partial derivative of the lower bound L(q) w.r.t to ωk, pij and ξj be 0 to get the
variational parameters ωk, pij and ξj :
ωk =
1
1 + exp (−uk) , where uk = log
ω
1− ω +
1
2
log
s2k
σ2
+
µ2k
2s2k
,
vj = logα+ (α− 1) log pj + Zjb +
K∑
k=1
Ajkωkµk,
ξ2j =
(
Zjb +
∑
k
Ajkωkµk
)2
+
∑
k
A2jk
(
ωk
(
s2k + µ
2
k
)− ω2kµ2k) .
The variational lower bound L(q) is
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L(q)
=
M∑
j=1
(pij (logα+ (α− 1) log pj))
+
M∑
j=1
pij (Zjb +∑
k
Ajkωkµk
)
+ logS (ξj)− λ (ξj)
(β0 +∑
k
Ajkωkµk
)2
− ξ2j

+
M∑
j=1
(
−
(
Zjb +
∑
k
Ajkωkµk + ξj
)
/2 + λ (ξj)
∑
k
A2jkω
2
kµ
2
k − λ (ξj)
∑
k
A2jkωk
(
s2k + µ
2
k
))
− 1
2σ2
K∑
k=1
(
ωk
(
s2k + µ
2
k
)− ωkσ2)+ K∑
k=1
ωk logω +
K∑
k=1
(1− ωk) log (1− ω)
+
K∑
k=1
(
1
2
ωk
(
log s2k − log σ2
)− ωk logωk − (1− ωk) log (1− ωk))
−
M∑
j=1
(pij log pij + (1− pij) log (1− pij)) .
M-step
Now we update α, b, σ2, ω. We set the partial derivative of L(q) w.r.t the parameters to be 0 and
get
α = −
∑M
j=1 pij∑M
j=1 pij log pj
,
σ2 =
∑K
k=1 ωk
(
s2k + µ
2
k
)∑K
k=1 ωk
,
ω =
1
K
K∑
k=1
ωk,
and use Newton’s method to update b:
b = bold −H−1g,
where
g =
M∑
j=1
ZTj
(
pij − 2λ (ξj)
(
Zjb +
∑
k
Ajkωkµk
)
− 1
2
)
,
H = −2ZTj λ (ξj)Zj .
Implementation
• Initialize α, σ2, ω, b, {ωk, µk}k=1,...K , {ξj , pij}j=1,...,M . Let y˜ =
∑
k Ajkωkµk.
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• E-step: For i = 1, ...,K, first obtain y˜i = y˜ − Ajiωiµi, and then update µi, s2i , ωi and y˜ as
follows
s2i =
σ2
1 + 2σ2
∑M
j=1 λ (ξj)A
2
ji
,
µi = s
2
i
M∑
j=1
((
pij − 1
2
− 2λ (ξj) (Zjb + y˜i)
)
Aji
)
,
ωi =
1
1 + exp (−ui) , where ui = log
ω
1− ω +
1
2
log
s2i
σ2
+
µ2i
2s2i
,
y˜ = y˜i +Ajiωiµi.
Then for j = 1, ...,M , update pij , ξj as follows
pij =
1
1 + exp (−vj) , where vj = logα+ (α− 1) log pj + Zjb + y˜,
ξ2j = (Zjb + y˜)
2
+
∑
k
A2jk
(
ωk
(
s2k + µ
2
k
)− ω2kµ2k) .
Calculate L (q):
L(q)
=
M∑
j=1
pij (logα+ (α− 1) log pj)−
M∑
j=1
(pij log pij + (1− pij) log (1− pij))
+
M∑
j=1
(
pij (Zjb + y˜) + logS (ξj)− Zjb + y˜ + ξj
2
)
− 1
2σ2
K∑
k=1
(
ωk
(
s2k + µ
2
k
)− ωkσ2)+ K∑
k=1
ωk logω +
K∑
k=1
(1− ωk) log (1− ω)
+
K∑
k=1
(
1
2
ωk
(
log s2k − log σ2
)− ωk logωk − (1− ωk) log (1− ωk)) .
• M-step
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α = −
∑M
j=1 pij∑M
j=1 pij log pj
,
σ2 =
∑K
k=1 ωk
(
s2k + µ
2
k
)∑K
k=1 ωk
,
ω =
1
K
K∑
k=1
ωk,
g = −
M∑
j=1
ZTj
(
pij − 2λ (ξj) (Zjb + y˜)− 1
2
)
,
H = 2
M∑
j=1
λ (ξj)Z
T
j Zj ,
b = bold −H−1g.
• Evaluate L(q) to track the convergence of the algorithm.
2 Details of the proposed algorithm
Stage 1: Two-groups model (TGM)
Suppose we have the p-values of M SNPs for a given a phenotype. Let γj be the latent variables
indicating whether the j-th SNP is associated with this phenotype. Here γj = 0 means unassociated
and γj = 1 means associated. Then we have the following two-groups model:
pj ∼
U [0, 1] , γj = 0,Beta (α, 1) , γj = 1,
where p ∈ RM are the p-values, 0 < α < 1 and Pr (γj = 1) = pi1.
We can use EM algorithm to compute the posterior and parameter estimation.
Let θ = {α, pi1} be the collection of model parameters. The logarithm of the marginal likelihood
is
log Pr (p|θ) = log
∑
γ
Pr (p,γ|θ) = log
∑
γ
Pr (p|γ;α) Pr (γ|pi1) ,
where
Pr (p|γ;α) =
M∏
j=1
Pr (pj |γj ;α) =
M∏
j=1
(
αpα−1j
)γj
,
Pr (γ|pi1) =
M∏
j=1
pi
γj
1 (1− pi1)1−γj .
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In the E step, we compute the posterior:
γ˜j = q (γj = 1) =
pi1αp
α−1
j
pi1αp
α−1
j + 1− pi1
,
and get the Q function:
Q = Eq [log Pr (p|γ;α) + log Pr (γ|pi1)]
=
M∑
j=1
γ˜j (logα+ (α− 1) log pj + log pi1) +
M∑
j=1
(1− γ˜j) log (1− pi1) .
The incomplete log likelihood can be evaluated as:
L =
M∑
j=1
γ˜j (logα+ (α− 1) log pj + log pi1 − log γ˜j) +
M∑
j=1
(1− γ˜j) (log (1− pi1)− log (1− γ˜j)) .
In the M step, we update α and pi1 by maximizing the Q function. We have
α = −
∑M
j=1 γ˜j∑M
j=1 γ˜j log pj
,
pi1 =
1
M
M∑
j=1
γ˜j .
Algorithm:
Input: p, Initialize: α = 0.1, pi1 = 0.1, Output: α, pi1, {γ˜j}j=1,...,M .
• Initialize α = 0.1, pi1 = 0.1.
• E-step: For j = 1, ...,M , calculate γ˜j as follows
γ˜j =
pi1αp
α−1
j
pi1αp
α−1
j + 1− pi1
.
Calculate L:
L =
M∑
j=1
γ˜j (logα+ (α− 1) log pj + log pi1 − log γ˜j) +
M∑
j=1
(1− γ˜j) (log (1− pi1)− log (1− γ˜j)) .
• M-step:
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α = −
∑M
j=1 γ˜j∑M
j=1 γ˜j log pj
,
pi1 =
1
M
M∑
j=1
γ˜j .
• Check convergence.
Stage 2: Latent fixed-effect model (LFM)
Suppose we have the p-values of M SNPs for a given a phenotype. Similarly, we assume
pj ∼
U [0, 1] , γj = 0,Beta (α, 1) , γj = 1,
where p ∈ RM are the p-values, γj = 1 indicates the j-th is associated with this phenotype and
γj = 0 otherwise, and 0 < α < 1.
To integrate more information, we consider the logistic fixed-effect model:
log
Pr (γj = 1|Zj)
Pr (γj = 0|Zj) = Zjb,
where Z ∈ RM×(L+1) and b = [b0, b1, b2, ..., bL]T is an unknown vector of fixed effects, L is the
number of covariates.
We can use EM algorithm to compute the posterior and parameter estimation.
Let θ = {α,b} be the collection of model parameters. The complete data likelihood can be
written as
Pr (p,γ|Z;θ) = Pr (p|γ;α) Pr (γ|Z;b) ,
where
Pr (p|γ;α) =
M∏
j=1
Pr (pj |γj ;α) =
M∏
j=1
(
αpα−1j
)γj
,
Pr (γ|Z;b) =
M∏
j=1
eγjZjbS (−Zjb) .
In the E step, we compute the posterior:
γ˜j = q (γj = 1) =
eZjbαpα−1j
eZjbαpα−1j + 1
,
and get the Q function:
Q =
M∑
j=1
γ˜j (logα+ (α− 1) log pj + Zjb) +
M∑
j=1
logS (−Zjb) .
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The incomplete log likelihood can be evaluated as:
L =
M∑
j=1
γ˜j (logα+ (α− 1) log pj + Zjb− log γ˜j)−
M∑
j=1
(1− γ˜j) log (1− γ˜j) +
M∑
j=1
logS (−Zjb) .
In the M step, we update α by maximizing the Q function. We have
α = −
∑M
j=1 γ˜j∑M
j=1 γ˜j log pj
.
We use Newton’s method to update b:
b = bold −H−1g,
where
g =
M∑
j=1
(−γ˜j + S (Zjb))Zj ,
H =
M∑
j=1
S (Zjb)S (−Zjb)ZTj Zj .
Algorithm:
Input: p, Z, α, b0 = log pi11−pi1 , Output: α, b, {γ˜j}j=1,...,M .
• Initialize α, b = (b0, 0, ..., 0)T .
• E-step: For j = 1, ...,M , calculate γ˜j as follows
γ˜j = q (γj = 1) =
eZjbαpα−1j
eZjbαpα−1j + 1
.
Calculate L:
L =
M∑
j=1
γ˜j (logα+ (α− 1) log pj + Zjb− log γ˜j)−
M∑
j=1
(1− γ˜j) log (1− γ˜j) +
M∑
j=1
logS (−Zjb) .
• M-step
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α = −
∑M
j=1 pij∑M
j=1 pij log pj
,
g =
M∑
j=1
(−γ˜j + S (Zjb))Zj ,
H =
M∑
j=1
S (Zjb)S (−Zjb)ZTj Zj ,
b = bold −H−1g.
• Check convergence.
Stage 3: Logistic sparse mixed model
Suppose we the latent states γ of M SNPs for a given phenotype is given. We consider a logistic
mixed model:
log
Pr (γj = 1|Zj ,Aj)
Pr (γj = 0|Zj ,Aj) = Zjb + Ajβ =
L∑
l=0
Zjlbl +
K∑
k=1
Ajkβk,
where Z ∈ RM×(L+1), A ∈ RM×K , b = [b0, b1, b2, ..., bL]T is an unknown vector of fixed effects,
β = [β1, β2, ..., βK ]
T is a unknown vector of random effects with a sprike-slab prior:
βk ∼
N
(
0, σ2
)
, ηk = 1,
δ0, ηk = 0,
where ηk is another latent variable with Pr (ηk = 1) = ω. Here ηk = 1 means the k-th annotation is
relevant to this phenotype and ηk = 0 otherwise.
To handle the Dirac function, we reparemeterize the spike-slab prior as β˜k ∼ N
(
0, σ2
)
, then
βk = ηkβ˜k.
We can use variational EM algorithm to compute the posterior and parameter estimation.
Let θ =
{
α,b, σ2, ω
}
be the collection of model parameters. Using the sigmoid function denoted
as S (x) = 11+e−x , the complete data likelihood can be written as
Pr
(
γ, β˜,η|Z,A;θ
)
= Pr
(
γ|Z,A, β˜,η;b
)
Pr
(
β˜,η|σ2, ω
)
,
where
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Pr
(
γ|Z,A, β˜,η;b
)
=
M∏
j=1
Pr
(
γj |Zj ,Aj , β˜,η;b
)
=
M∏
j=1
eγj(Zjb+
∑
k Ajkηkβ˜k)S
(
−Zjb−
∑
k
Ajkηkβ˜k
)
,
Pr
(
β˜,η|σ2, ω
)
=
K∏
k=1
Pr
(
β˜k, ηk|σ2, ω
)
=
K∏
k=1
N
(
β˜k|0, σ2
)
ωηk (1− ω)1−ηk .
We can use JJ bound [Jaakkola and Jordan, 2000] to bound the sigmoid function by
S (x) ≥ S (ξ) exp{(x− ξ) /2− λ (ξ) (x2 − ξ2)} ,
where λ (ξ) = 12ξ
[
S (ξ)− 12
]
. Using this bound, we have a tractable lower bound of Pr
(
γ|Z,A, β˜,η;b
)
which is denoted by h
(
γ|Z,A, β˜,η;b, ξ
)
:
h
(
γj |Zj ,Aj , β˜,η;b, ξj
)
= eγj(Zjb+
∑
k Ajkηkβ˜k)S (ξj) exp
−λ (ξj)
(Zjb +∑
k
Ajkηkβ˜k
)2
− ξ2j
− Zjb +∑k Ajkηkβ˜k + ξj
2
 .
Next, Let q
(
β˜,η
)
be an approximation of the posterior Pr
(
β˜,η|Z,A;θ
)
. Then we can obtain
a lower bound of the logarithm of the marginal likelihood:
log Pr (γ|Z,A;θ)
= log
∑
η
ˆ
Pr
(
γ, β˜,η|Z,A;θ
)
dβ˜
= log
∑
η
ˆ
Pr
(
γ|Z,A, β˜,η;b
)
Pr
(
β˜,η|σ2, ω
)
dβ˜
≥ log
∑
η
ˆ
h
(
γ|Z,A, β˜,η;b, ξ
)
Pr
(
β˜,η|σ2, ω
)
dβ˜
≥
∑
η
ˆ
q
(
β˜,η
)
log
h
(
γ|Z,A, β˜,η;b, ξ
)
Pr
(
β˜,η|σ2, ω
)
q
(
β˜,η
) dβ˜
= Eq
[
log h
(
γ|Z,A, β˜,η;b, ξ
)
+ log Pr
(
β˜,η|σ2, ω
)
− log q
(
β˜,η
)]
, L (q) ,
where L(q) is the lower bound. The second inequality follows Jensen’s inequality. We can maximize
L(q) instead of the marginal likelihood to get parameter estimations. To make it feasible to evaluate
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the lower bound, we assume that q
(
β˜,η
)
can be factorized as
q
(
β˜, η
)
=
K∏
k=1
q
(
β˜k, ηk
)
=
K∏
k=1
q
(
β˜k|ηk
)
q (ηk) ,
where q (ηk = 1) = ωk.
We can obtain an approximation according to the mean-field method:
log q
(
β˜i, ηi
)
= Ek 6=i
[
log h
(
γ|Z,A, β˜,η,b, ξ
)
+ log Pr
(
β˜,η|σ2, ω
)]
,
where the expectation is taken under the distribtion q
(
β˜−i, η−i
)
=
∏
k 6=i q
(
β˜k, ηk
)
. Then we have
q
(
β˜i, ηi
)
=
[
ωiN
(
µi, s
2
i
)]ηi [
(1− ωi)N
(
0, σ2
)]1−ηi
,
where
µi = s
2
i
M∑
j=1
pij − 1
2
− 2λ (ξj)
Zjb +∑
k 6=i
AjkEk
[
ηkβ˜k
]Aji,
s2i =
σ2
1 + 2σ2
∑M
j=1 λ (ξj)A
2
ji
.
Then we maximize L (q) with respect to ωk and ξj and get
ωk =
1
1 + exp (−uk) , where uk = log
ω
1− ω +
1
2
log
s2k
σ2
+
µ2k
2s2k
,
ξ2j =
(
Zjb +
∑
k
Ajkωkµk
)2
+
∑
k
A2jk
(
ωk
(
s2k + µ
2
k
)− ω2kµ2k) .
Now we have evaluate L(q):
L(q)
=
M∑
j=1
γj (Zjb +∑
k
Ajkωkµk
)
+ logS (ξj)− λ (ξj)
(Zjb +∑
k
Ajkωkµk
)2
− ξ2j

+
M∑
j=1
(
−
(
Zjb +
∑
k
Ajkωkµk + ξj
)
/2 + λ (ξj)
∑
k
A2jkω
2
kµ
2
k − λ (ξj)
∑
k
A2jkωk
(
s2k + µ
2
k
))
− 1
2σ2
K∑
k=1
(
ωk
(
s2k + µ
2
k
)− ωkσ2)+ K∑
k=1
ωk logω +
K∑
k=1
(1− ωk) log (1− ω)
+
K∑
k=1
(
1
2
ωk
(
log s2k − log σ2
)− ωk logωk − (1− ωk) log (1− ωk)) .
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With q
(
γ, β˜,η
)
obtained, we can evaluate the lower bound and then update the model param-
eters by maximizing L(q).
In the M step, we update σ2 and ω by maximizing L(q). We have
σ2 =
∑K
k=1 ωk
(
s2k + µ
2
k
)∑K
k=1 ωk
,
ω =
1
K
K∑
k=1
ωk.
We use Newton’s method to update b:
b = bold −H−1g,
where
g = −
M∑
j=1
ZTj
(
γj − 2λ (ξj)
(
Zjb +
∑
k
Ajkωkµk
)
− 1
2
)
,
H = 2
M∑
j=1
λ (ξj)Z
T
j Zj .
Algorithm:
Input: Z, A, {γj = γ˜j}j=1,...,M , b, Initialize: σ2 = 1, ω = 0.5, {ωk = 0, µk = 0}k=1,...K , ξ = Zb,
Output: b, ξ, σ2, ω, {ωk, µk}k=1,...K .
• Initialize b, ξ = Zb, σ2 = 1, ω = 0.5, {ωk = 0, µk = 0}k=1,...K . Let y˜ =
∑
k Ajkωkµk.
• E-step: For i = 1, ...,K, first obtain y˜i = y˜ − Ajiωiµi, and then update µi, s2i , ωi and y˜ as
follows
s2i =
σ2
1 + 2σ2
∑M
j=1 λ (ξj)A
2
ji
,
µi = s
2
i
M∑
j=1
((
γj − 1
2
− 2λ (ξj) (Zjb + y˜i)
)
Aji
)
,
ωi =
1
1 + exp (−ui) , where ui = log
ω
1− ω +
1
2
log
s2i
σ2
+
µ2i
2s2i
,
y˜ = y˜i +Ajiωiµi.
Then for j = 1, ...,M , update ξj as follows
ξ2j = (Zjb + y˜)
2
+
∑
k
A2jk
(
ωk
(
s2k + µ
2
k
)− ω2kµ2k) .
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Calculate L (q):
L(q)
=
M∑
j=1
(
γj (Zjb + y˜) + logS (ξj)− Zjb + y˜ + ξj
2
)
− 1
2σ2
K∑
k=1
(
ωk
(
s2k + µ
2
k
)− ωkσ2)+ K∑
k=1
ωk logω +
K∑
k=1
(1− ωk) log (1− ω)
+
K∑
k=1
(
1
2
ωk
(
log s2k − log σ2
)− ωk logωk − (1− ωk) log (1− ωk)) .
• M-step
g = −
M∑
j=1
ZTj
(
pij − 2λ (ξj) (Zjb + y˜)− 1
2
)
,
H = 2
M∑
j=1
λ (ξj)Z
T
j Zj ,
b = bold −H−1g,
σ2 =
∑K
k=1 ωk
(
s2k + µ
2
k
)∑K
k=1 ωk
,
ω =
1
K
K∑
k=1
ωk.
• Check convergence.
Stage 4: LSMM
Input: p, Z, A, α,b, ξ, σ2, ω, {ωk, µk}k=1,...K , Initialize: {pij = γ˜j}j=1,...,M , Output: α,b, σ2, ω,
{ωk, βk = µkωk}k=1,...K , {pij}j=1,...,M
Algorithm:
• Initialize α, σ2, ω, b, {ωk, µk}k=1,...K , {ξj , pij}j=1,...,M . Let y˜ =
∑
k Ajkωkµk.
• E-step: For i = 1, ...,K, first obtain y˜i = y˜ − Ajiωiµi, and then update µi, s2i , ωi and y˜ as
follows
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s2i =
σ2
1 + 2σ2
∑M
j=1 λ (ξj)A
2
ji
,
µi = s
2
i
M∑
j=1
((
pij − 1
2
− 2λ (ξj) (Zjb + y˜i)
)
Aji
)
,
ωi =
1
1 + exp (−ui) , where ui = log
ω
1− ω +
1
2
log
s2i
σ2
+
µ2i
2s2i
,
y˜ = y˜i +Ajiωiµi.
Then for j = 1, ...,M , update pij , ξj as follows
pij =
1
1 + exp (−vj) , where vj = logα+ (α− 1) log pj + Zjb + y˜,
ξ2j = (Zjb + y˜)
2
+
∑
k
A2jk
(
ωk
(
s2k + µ
2
k
)− ω2kµ2k) .
Calculate L (q):
L(q)
=
M∑
j=1
pij (logα+ (α− 1) log pj)−
M∑
j=1
(pij log pij + (1− pij) log (1− pij))
+
M∑
j=1
(
pij (Zjb + y˜) + logS (ξj)− Zjb + y˜ + ξj
2
)
− 1
2σ2
K∑
k=1
(
ωk
(
s2k + µ
2
k
)− ωkσ2)+ K∑
k=1
ωk logω +
K∑
k=1
(1− ωk) log (1− ω)
+
K∑
k=1
(
1
2
ωk
(
log s2k − log σ2
)− ωk logωk − (1− ωk) log (1− ωk)) .
• M-step
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α = −
∑M
j=1 pij∑M
j=1 pij log pj
,
σ2 =
∑K
k=1 ωk
(
s2k + µ
2
k
)∑K
k=1 ωk
,
ω =
1
K
K∑
k=1
ωk,
g = −
M∑
j=1
ZTj
(
pij − 2λ (ξj) (Zjb + y˜)− 1
2
)
,
H = 2
M∑
j=1
λ (ξj)Z
T
j Zj ,
b = bold −H−1g.
• Evaluate L(q) to track the convergence of the algorithm.
3 Simulation study for evaluating the LD effects on LSMM
To study the influence of LD effects on our LSMM, we used the observed genotype data (1,500
individuals from the 1958 British Birth Cohort (58C)) from WTCCC (The Wellcome Trust Case
Control Consortium, 2007). For simplicity, we only consider 23874 SNPs in chromosome 1 after
quality control. We simulated a risk SNP every 1000 SNPs. So we had 24 risk SNPs. We assumed
the 24 risk SNPs can explain 5% phenotypic variance. We used GCTA to simulation phenotypes
and used PLINK to get p-values for SNPs. Then we applied LSMM and detect risk SNPs.
As the presence of LD effects, SNPs in a local genomic region would be correlated and detection
of risk SNPs would be difficult. We are just expected to identify the region which contains the risk
SNPs. Here we used different distance threshold to define the region around true risk SNPs. The
identified risk SNPs which in the region of true risk SNPs were considered as true positive.
We considered four cases. The first case, no effects, means we only used the p-values and didn’t
use fixed effects and random effects. In the second case, fixed effects, we only add 10 fixed effects. In
the fixed effects, SNPs within 1Mb of true risk SNPs are annotated with a probability of 0.6. In the
third case, fixed + random effects, we further add 100 random effects in which SNPs are annotated
randomly. In the fourth case, fixed + relevant random effects, we assume 20% of random effects are
relevant to the phenotype and SNPs within 1Mb of true risk SNPs are annotated with a probability
of 0.6 in the relevant random effects. The results of observed FDR were shown in Figure S1 based on
50 simulations. In the first case, when we used no effects, the observed FDR was quite stable at 0.1.
When we added fixed effects and random effects, the observed FDR was just inflated a little with
the smallest distance threshold and became conservative as the distance threshold increased. As a
result, we believe that LSMM can provide a satisfactory FDR control in detecting a local genomic
region of risk SNPs.
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Figure S1: FDR of LSMM for identification of risk SNPs with different distance thresholds. The red
line indicates the threshold of global FDR τ = 0.1.
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4 More simulation results for different settings
4.1 Performance in identification of risk SNPs
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Figure S2: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.2 and K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S3: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.4 and K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S4: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.6 and K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S5: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.4 and K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S6: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.6 and K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S7: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.2 and K = 1000. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S8: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.4 and K = 1000. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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Figure S9: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs with α = 0.6 and K = 1000. We controlled global FDR at 0.1 to evaluate empirical FDR and
power. The results are summarized from 50 replications.
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4.2 Performance in identification of risk SNPs if treat all covariates as
fixed effects
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Figure S10: FDR of LSMM and LSMM (treat all covariates as fixed effects) for identification of risk
SNPs with K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and power. The
results are summarized from 50 replications.
4.3 Performance in identification of relevant annotations
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Figure S11: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations
with α = 0.2 and K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S12: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations
with α = 0.4 and K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S13: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations
with α = 0.6 and K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S14: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations
with α = 0.4 and K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S15: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations
with α = 0.6 and K = 500. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S16: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations with
α = 0.2 and K = 1000. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S17: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations with
α = 0.4 and K = 1000. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
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Figure S18: FDR, power, AUC and partial AUC of LSMM for detection of relevant annotations with
α = 0.6 and K = 1000. We controlled global FDR at 0.1 to evaluate empirical FDR and power.
The results are summarized from 50 replications.
4.4 Performance in identification of relevant annotations when fixed ef-
fects and random effects are not independent
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Figure S19: FDR of LSMM and LSMM without fixed effects for detection of relevant annotations
with K = 100. We controlled global FDR at 0.1 to evaluate empirical FDR and power. The results
are summarized from 50 replications.
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4.5 Simulations based on probit model
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Figure S20: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs based on probit model with K = 100. We controlled global FDR at 0.1 to evaluate empirical
FDR and power. The results are summarized from 50 replications.
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Figure S21: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for identification of risk
SNPs based on probit model with K = 1000. We controlled global FDR at 0.1 to evaluate empirical
FDR and power. The results are summarized from 50 replications.
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Figure S22: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for detection of relevant
annotations based on probit model with K = 100. We controlled global FDR at 0.1 to evaluate
empirical FDR and power. The results are summarized from 50 replications.
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Figure S23: FDR, power, AUC and partial AUC of LSMM, LFM and TGM for detection of relevant
annotations based on probit model with K = 1000. We controlled global FDR at 0.1 to evaluate
empirical FDR and power. The results are summarized from 50 replications.
4.6 Simulations if p-values are not from beta distribution
In the model setting of the LSMM, we assume that p-values are from the mixture of uniform and
Beta distributions. To check the robustness of our method, we conducted simulations as follows.
We first generated z-scores and then converted them to p-values. Here z-values from the null group
follow the standard normal distribution and z-values from the non-null group follow the alternative
distributions in Table S1. In these simulations, the p-values in non-null group converted from z-
scores will not from Beta distribution. We evaluated the FDR, power and AUC. The results are
shown in Figures S24-S26.
Scenario Distribution
spiky 0.4N
(
0, 0.252
)
+ 0.2N
(
0, 0.52
)
+ 0.2N
(
0, 12
)
+ 0.2N
(
0, 22
)
near normal 2
3
N
(
0, 12
)
+ 1
3
N
(
0, 22
)
skew 1
4
N
(−2, 22)+ 1
4
N
(−1, 1.52)+ 1
3
N
(
0, 12
)
+ 1
6
N
(
1, 12
)
big-normal N
(
0, 42
)
Table S1: Alternative distributions for z-scores.
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Figure S24: FDR of LSMM, LFM and TGM with K = 100. We controlled global FDR at 0.1 to
evaluate empirical FDR. The results are summarized from 50 replications.
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Figure S25: FDR of LSMM, LFM and TGM with K = 500. We controlled global FDR at 0.1 to
evaluate empirical FDR. The results are summarized from 50 replications.
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Figure S26: FDR of LSMM, LFM and TGM with K = 1000. We controlled global FDR at 0.1 to
evaluate empirical FDR. The results are summarized from 50 replications.
4.7 Comparison between LSMM and GPA
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Figure S27: FDR, power, AUC and partial AUC LSMM, LSMM without fixed effects and GPA for
identification of risk SNPs with K = 100. We controlled global FDR at 0.1 to evaluate empirical
FDR and power. The results are summarized from 50 replications.
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Figure S28: FDR, power, AUC and partial AUC LSMM, LSMM without fixed effects and GPA for
identification of risk SNPsn with K = 50. We controlled global FDR at 0.1 to evaluate empirical
FDR and power. The results are summarized from 50 replications.
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Figure S29: FDR, power, AUC and partial AUC LSMM, LSMM without fixed effects and GPA for
identification of risk SNPs with K = 10. We controlled global FDR at 0.1 to evaluate empirical
FDR and power. The results are summarized from 50 replications.
4.8 Comparison between LSMM and cmfdr
We compared LSMM with cmfdr. As cmfdr is not able to handle a large number of covariates and
the MCMC sampling algorithm it derived is time-consuming, we set M = 5000, L = 5, K = 5 and
run 2500 iterations with 2000 retained draws for cmfdr. The comparison between LSMM and cmfdr
are shown in Figure S30.
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Figure S30: FDR, power, AUC and partial AUC of LSMM and cmfdr for identification of risk SNPs.
We controlled global FDR at 0.1 to evaluate empirical FDR and power. The results are summarized
from 50 replications.
4.9 Estimation of parameters
4.9.1 Estimation of α
We evaluate the performance of LSMM in estimation of parameter α in the beta distribution. We
compare LSMM with the other three methods, TGM (without fixed effects and random effects),
LFM (with only fixed effects) and LSMM without fixed effects. We varied ω at {0, 0.25, 0.5, 0.75, 1}.
Figures S31-S33 show the comparision among these methods with α = 0.2, 0.4 and 0.6 respectively.
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
K = 100 K = 500 K = 1000
0 0.25 0.5 0.75 1 0 0.25 0.5 0.75 1 0 0.25 0.5 0.75 1
0.195
0.200
0.205
omega
 
Es
tim
at
io
n 
of
 a
lp
ha
LSMM LSMM without fixed effects LFM TGM
Figure S31: Perfermance in estimation of parameter α when the true α = 0.2.
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Figure S32: Perfermance in estimation of parameter α when the true α = 0.4.
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Figure S33: Perfermance in estimation of parameter α when the true α = 0.6.
4.9.2 Estimation of b
We evaluate the performance of LSMM in estimation of parameter β0 and b. We varied ω at
{0, 0.25, 0.5, 0.75, 1}. Figures S34-S44 show the comparision between LSMM and LFM (with only
fixed effects) with α = 0.2, 0.4 and 0.6.
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Figure S34: Perfermance in estimation of parameter b0.
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Figure S35: Perfermance in estimation of parameter b1.
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Figure S36: Perfermance in estimation of parameter b2.
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Figure S37: Perfermance in estimation of parameter b3.
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Figure S38: Perfermance in estimation of parameter b4.
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Figure S39: Perfermance in estimation of parameter b5.
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Figure S40: Perfermance in estimation of parameter b6.
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Figure S41: Perfermance in estimation of parameter b7.
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Figure S42: Perfermance in estimation of parameter b8.
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Figure S43: Perfermance in estimation of parameter b9.
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Figure S44: Perfermance in estimation of parameter b10.
4.9.3 Estimation of ω
We evaluate the performance of LSMM in estimation of parameter ω which measures the proportion
of relevant annotations. We varied ω at {0, 0.25, 0.5, 0.75, 1}. Figure S45 shows the results with
α = 0.2, 0.4 and 0.6.
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Figure S45: Perfermance in estimation of parameter ω.
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5 More about real data analysis
5.1 The source of the 30 GWAS
Alzheimer Lambert et al., 2013, Nature Genetics. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
BMI Speliotes et al., 2010, Nature Genetics. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Bipolar Disorder Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011, Nature Genetics
https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Coronary Artery Disease Schunkert et al., 2011, Nature Genetics. http://www.cardiogramplusc4d.org/data-downloads
Crohns Disease Jostins et al., 2012, Nature. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Height Wood et al., 2014, Nature Genetics
http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files
High-density Lipoprotein Global Lipids Genetics Consortium, 2013, Nature Genetics
http://csg.sph.umich.edu//abecasis/public/lipids2013/
HIV McLaren et al., 2013, PLoS Pathogens
http://journals.plos.org/plospathogens/article?id=10.1371%2Fjournal.ppat.1003515
Inflammatory Bowel Disease Jostins et al., 2012, Nature. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Low-density Lipoprotein Global Lipids Genetics Consortium, 2013, Nature Genetics
http://csg.sph.umich.edu//abecasis/public/lipids2013/
Lupus Bentham et al., 2015, Nature Genetics
https://www.immunobase.org/downloads/protected_data/GWAS_Data/
Mean Cell Haemoglobin Pickrell, 2014, The American Journal of Human Genetics
https://ega-archive.org/studies/EGAS00000000132
Mean Cell Volume Pickrell, 2014, The American Journal of Human Genetics
https://ega-archive.org/studies/EGAS00000000132
Menopause Day et al., 2015, Nature Genetics. http://www.reprogen.org/data_download.html
Multiple Sclerosis Sawcer et al., 2011, Nature. https://www.immunobase.org/downloads/protected_data/GWAS_Data/
Neuroticism Okbay et al., 2016a, Nature Genetics. http://ssgac.org/documents/Neuroticism_Full.txt.gz
Primary Biliary Cirrhosis Cordell et al., 2015, Nature Communications
https://www.immunobase.org/downloads/protected_data/GWAS_Data/
Red Cell Count Pickrell, 2014, The American Journal of Human Genetics
https://ega-archive.org/studies/EGAS00000000132
Rheumatoid Arthritis Okada et al., 2014, Nature. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Schizophrenia1 Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013, The Lancet.
https://www.med.unc.edu/pgc/results-and-downloads (SCZ subset)
Schizophrenia2 Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, 2011, Nature Genetics.
https://www.med.unc.edu/pgc/results-and-downloads (SCZ1)
Schizophrenia3 Ripke et al., 2013, Nature Genetics. https://www.med.unc.edu/pgc/results-and-downloads (Sweden+SCZ1)
Schizophrenia4 Ripke et al., 2014, Nature. https://www.med.unc.edu/pgc/results-and-downloads (SCZ2)
Total Cholesterol Global Lipids Genetics Consortium, 2013, Nature Genetics
http://csg.sph.umich.edu//abecasis/public/lipids2013/
Triglycerides Global Lipids Genetics Consortium, 2013, Nature Genetics
http://csg.sph.umich.edu//abecasis/public/lipids2013/
Type 1 Diabetes Bradfield et al., 2011, PLoS Genetics
https://www.immunobase.org/downloads/protected_data/GWAS_Data/
Type 2 Diabetes Morris et al., 2012, Nature Genetics. http://diagram-consortium.org/downloads.html
Ulcerative Colitis Jostins et al., 2012, Nature. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Years of Education1 Rietveld et al., 2013, Science. https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Years of Education2 Okbay et al., 2016b, Nature. http://ssgac.org/documents/EduYears_Main.txt.gz
Table S2: The source of the 30 GWAS.
59
5.2 Four Schizophrenia GWAS with different sample sizes
Table S3: Summary of results for Schizophrenia.
αˆ
No. of risk SNPs
Bonferroni correction TGM LFM LSMM
Schizophrenia1 0.677 2 470 527 527
Schizophrenia2 0.633 7 2,107 2,404 2,405
Schizophrenia3 0.562 126 6,811 7,541 7,545
Schizophrenia4 0.413 1110 48,802 50,481 50,990
a. The estimate αˆ is obtained using LSMM.
b. The number of risk SNPs is reported based on global FDR ≤ 0.1.
Figure S46: Manhattan plots of Schizophrenia1-4 using TGM and LSMM. The red lines indicate
local fdr = 0.1. The green points denote the additional SNPs LSMM identied with FDR ≤ 0.1.
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5.3 Computational time for 30 GWAS
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Figure S47: Computational time using LSMM and cmfdr for 30 GWAS.
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5.4 Relevant functional annotations for 30 GWAS without fixed effects
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Figure S48: Relevant functional annotations for 30 GWAS without integrating genic category anno-
tations.
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